Application of luteolin in preparation of medicament for treating and preventing stomach cancer

Abstract

The invention relates to the application of luteolin in the preparation of a medicament for treating and preventing stomach cancer. The luteolin can inhibit the proliferation of BGC-823 cells in vitro; the half inhibitory concentration (IC50) is 37.88+/-5.81 mu mol/L; and a flow cytometry detects that the luteolin can retard the BGC-823 cells in a G2/M stage and induce the apoptosis of the cells. Real-time quantitative polymerase chain reaction (PCR) detection shows that, after acting on the BGC-823 in vitro, the luteolin can promote the expression of the genes of dual-specificity phosphatase 1 (DUSP1), dual-specificity phosphatase 2 (DUSP2), dual-specificity phosphatase 4 (DUSP4) and dual-specificity phosphatase 5 (DUSP5) and inhibit the expression of a CXCL16 gene serving as a chemotactic factor; westernbloting detects the expression of protein p-ERK and Akt; after acting on the BGC-823 in vitro, the luteolin can inhibit the expression of the protein p-ERK and Akt so as to inhibit the overhigh activity of the pathways of MAPK and Akt; and therefore, the effect of treating tumors is achieved. A prevention model for the stomach cancer in a nude mouse is established; the luteolin can prevent and inhibit the growth of the tumors in vivo; immunohistochemistry proves that the expression amounts of the protein HIF-1 alpha, vascular endothelial growth factor (VEGF) and MMP9 are obviously reduced and can inhibit the generation of tumor vasculature in vivo; and therefore, a theoretical foundation is provided for the new application of the luteolin in the preparation of the medicament for treating and preventing the stomach cancer.

Description

technical field [0001] The present invention relates to the use of luteolin, especially the use of luteolin in the preparation of medicines for treating and preventing gastric cancer. Background technique [0002] Gastric cancer is a common malignant tumor of the digestive system in the world, especially in China and Asia, the incidence rate is the first, and it currently ranks the third in cancer death in my country. Chemotherapy is the main treatment for gastric cancer, but the chemotherapeutic drugs are highly toxic, and long-term use is easy to form drug resistance; while surgical treatment is often used for middle-advanced patients, but postoperative recurrence and abdominal metastasis are easy, resulting in poor prognosis of gastric cancer and a 5-year survival rate. Less than 10%. Therefore, there is an urgent need to develop new treatments to improve the survival of gastric cancer patients. At the same time, the further clarification of the mechanism of occurrence ...

AI Technical Summary

Problems solved by technology

Chemotherapy is the main treatment for gastric cancer, but the chemotherapeutic drugs are highly toxic, and long-term use is easy to form drug resistance; while surgical treatment is often used for middle-advanced patients, but postoperative recurrence and abdominal metastasis are easy, resulting in poor prognosis of gastric cancer and a 5-year survival rate. Less than 10%

Before the publication of the present invention, there has not been any patent disclosure or report that luteolin can treat and prevent gastric tumors by inhibiting MAPK and Akt signaling pathways, and luteolin can up-regulate the expression of DUSP1-4 genes and inhibit the gene of CXCL-16 The expression is also reported for the first time

Images